Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor

HIV drug resistance against strand transfer integrase inhibitors

(2017) Kaitlin Anstett et al.   Retrovirology

Riches in RAGs: Revealing the V(D)J Recombinase through High-Resolution Structures

(2017) Karla K. Rodgers   TRENDS IN BIOCHEMICAL SCIENCES

HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination

(2017) Mayilaadumveettil Nishana et al.   Cell Death & Disease

Might dolutegravir be part of a functional cure for HIV?

(2016) Mark A. Wainberg et al.   CANADIAN JOURNAL OF MICROBIOLOGY

Identification and characterization of novel ligase I inhibitors

(2016) Monica Pandey et al.   MOLECULAR CARCINOGENESIS

Crystal structure of the V(D)J recombinase RAG1–RAG2

(2015) Min-Sung Kim et al.   NATURE

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor

(2015) Peter K. Quashie et al.   PLoS One

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

(2015) Christopher Kandel et al.   Drug Design Development and Therapy

Detection of G-Quadruplex DNA Using Primer Extension as a Tool

(2015) Rupa Kumari et al.   PLoS One

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

(2014) Bisher Akil et al.   ANTIVIRAL THERAPY

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

Dolutegravir: First Global Approval

(2013) Anita D. Ballantyne et al.   DRUGS

Next-Generation Integrase Inhibitors

(2013) Sharon L. Karmon et al.   DRUGS

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

A non-B DNA can replace heptamer of V(D)J recombination when present along with a nonamer: implications in chromosomal translocations and cancer

(2012) Mayilaadumveettil Nishana et al.   BIOCHEMICAL JOURNAL

Chromosomal translocations among the healthy human population: implications in oncogenesis

(2012) Mridula Nambiar et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients

(2012) F. Saladini et al.   CLINICAL MICROBIOLOGY AND INFECTION

Mechanism of Fragility atBCL2Gene Minor Breakpoint Cluster Region during t(14;18) Chromosomal Translocation

(2012) Mridula Nambiar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

V(D)J Recombination: Mechanisms of Initiation

(2011) David G. Schatz et al.   Annual Review of Genetics

Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution

(2011) Gregory D Huhn et al.   AIDS Research and Therapy

Cytosines, but Not Purines, Determine Recombination Activating Gene (RAG)-induced Breaks on Heteroduplex DNA Structures

(2010) Abani Kanta Naik et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structure of the RAG1 nonamer binding domain with DNA reveals a dimer that mediates DNA synapsis

(2009) Fang Fang Yin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir

(2009) G. B. Beck-Engeser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

(2009) Erik Serrao et al.   Retrovirology

An Immunodeficiency Disease withRAGMutations and Granulomas

(2008) Catharina Schuetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evidence for Ku70/Ku80 association with full-length RAG1

(2008) Prafulla Raval et al.   NUCLEIC ACIDS RESEARCH